170 related articles for article (PubMed ID: 38589831)
1. Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation.
Sun H; Shang J; Liu X; Ren S; Hu S; Wang X
BMC Cancer; 2024 Apr; 24(1):432. PubMed ID: 38589831
[TBL] [Abstract][Full Text] [Related]
2. Identifying
Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
PeerJ; 2023; 11():e16618. PubMed ID: 38099311
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract][Full Text] [Related]
4. High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
Liu X; Zhao X; Yang J; Wang H; Piao Y; Wang L
Eur J Haematol; 2023 Feb; 110(2):198-208. PubMed ID: 36335584
[TBL] [Abstract][Full Text] [Related]
5. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M
Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348
[TBL] [Abstract][Full Text] [Related]
6. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
[TBL] [Abstract][Full Text] [Related]
7. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
8. microRNA‑196a‑3p inhibits cell proliferation and promotes cell apoptosis by targeting ADP ribosylation factor 4 in diffuse large B‑cell lymphoma.
Fu J; Lou X; Wan S; Zhao X; Chen Z; Zhu M; Guo L; Wu D; Wang S
Oncol Rep; 2021 Feb; 45(2):764-775. PubMed ID: 33416178
[TBL] [Abstract][Full Text] [Related]
9. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma.
Yousefi Z; Sharifzadeh S; Zare F; Eskandari N
Mol Biol Rep; 2023 Feb; 50(2):1133-1145. PubMed ID: 36409389
[TBL] [Abstract][Full Text] [Related]
10. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
[TBL] [Abstract][Full Text] [Related]
11. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Zheng W; Lin Q; Issah MA; Liao Z; Shen J
BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
[TBL] [Abstract][Full Text] [Related]
12. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
13. CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma.
Shen M; Zhang Y; Tang L; Fu Q; Zhang J; Xu Y; Zeng H; Li Y
BMC Cancer; 2023 Oct; 23(1):978. PubMed ID: 37833632
[TBL] [Abstract][Full Text] [Related]
14. [Expression of miR-126 in Diffuse Large B-Cell Lymphoma and Its Biological Function].
Qiu C; Zhang QH; Wang GG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1415-1422. PubMed ID: 36208243
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
Peng W; Wu J; Feng J
Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
[TBL] [Abstract][Full Text] [Related]
16. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA TRIM52-AS1 sponges microRNA-577 to facilitate diffuse large B cell lymphoma progression via increasing TRIM52 expression.
Zhao F; Li S; Liu J; Wang J; Yang B
Hum Cell; 2022 Jul; 35(4):1234-1247. PubMed ID: 35676608
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
[TBL] [Abstract][Full Text] [Related]
19. MiR-645 regulates the proliferation and apoptosis of diffuse large B-cell lymphoma by targeting DACH1.
Wang R; Shen J; Su N; Wang Q; Zhang M; Liu C
Hum Cell; 2020 Oct; 33(4):1091-1098. PubMed ID: 32529465
[TBL] [Abstract][Full Text] [Related]
20. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.
Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
